Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
about
Competing risks model in screening for preeclampsia in twin pregnancies by maternal factors and biomarkers at 11-13 weeks' gestation.Impaired placentation in women with chronic hypertension that develop preeclampsia.Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in prediction of pre-eclampsia.Strategies for investigating the maternal-fetal interface in the first trimester of pregnancy: What can we learn about pathology?Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for other major defects and pregnancy complications.Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.Accuracy of second trimester prediction of preterm preeclampsia by three different screening algorithms.The association of first trimester uterine arteries Doppler velocimetry with different clinical phenotypes of hypertensive disorders of pregnancy: a longitudinal study.Comparative Study of Abdominal Versus Transvaginal Ultrasound for Uterine Artery Doppler Velocimetry at 11 to 13 Weeks.Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: a historical cohort study.Competing-risks model in screening for pre-eclampsia in twin pregnancy by maternal characteristics and medical history.Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations.Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.Peripheral blood cell microRNA quantification during the first trimester predicts preeclampsia: Proof of concept.Role of angiogenic factors in the pathogenesis and management of pre-eclampsia.Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction - implications for treating preeclampsia.Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
P2860
Q38757227-F003CB2A-2B66-4AF7-999F-8430310E8E2DQ38805483-6B9E42BB-9600-48E3-8097-4FD79599BC90Q39025500-E1C05D1F-3474-4F5F-B5BB-C56B62CE4CB3Q39307767-FB5F8B47-3BB1-45E3-B996-36C893878351Q39429807-E4E3CC22-030E-4377-B617-CC43F4A12F36Q39431976-6E2542C0-3EC9-4901-A505-CB6767E400F6Q42373442-0F5A244D-2E2D-4004-B902-FF27D1543352Q47285655-516A45C6-CA1E-4E86-B4A5-4D7F15B0E2AAQ47441698-2A638526-30F1-4CEB-BFFC-DBDB6D76C1D2Q47562332-32074629-526B-47FB-BB56-0D658BB9DA1AQ47579497-AB90803A-6555-4BB1-84DD-2FB0EDA1B907Q47843646-9FBC05B7-4BA4-4C76-88EB-0222BB41EF0EQ47929307-B4EF0E8C-C3DC-4402-A5D7-BE75FEECA20BQ48099333-E9894992-A578-4CF8-AB7B-F51CCF64CC23Q48321056-34D2F894-CF30-431E-AD1E-503F587E918DQ49984490-20144DE0-8C08-453F-9356-6D3814F08D9FQ50343421-9ECF4CA9-E998-425D-A954-31CAD3F38DC8Q50579452-F1721B48-B6C6-4C54-9F28-860BEF49A4B4
P2860
Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Accuracy of competing-risks mo ...... ers at 11-13 weeks' gestation.
@en
Accuracy of competing-risks mo ...... ers at 11-13 weeks' gestation.
@nl
type
label
Accuracy of competing-risks mo ...... ers at 11-13 weeks' gestation.
@en
Accuracy of competing-risks mo ...... ers at 11-13 weeks' gestation.
@nl
prefLabel
Accuracy of competing-risks mo ...... ers at 11-13 weeks' gestation.
@en
Accuracy of competing-risks mo ...... ers at 11-13 weeks' gestation.
@nl
P2093
P2860
P50
P356
P1476
Accuracy of competing-risks mo ...... kers at 11-13 weeks' gestation
@en
P2093
C de Paco Matallana
F S Molina
K H Nicolaides
N O'Gorman
N Papantoniou
P2860
P304
P356
10.1002/UOG.17399
P577
2017-05-14T00:00:00Z